Retapamulinis atopicalantibioticdeveloped byGlaxoSmithKline. It is the first drug in the new class ofpleuromutilinantibiotics to be approved for human use. It is marketed as an ointment under the brand namesAltabaxandAltargo.
Retapamulin was approved by theUnited StatesFood and Drug Administrationin April 2007 for the treatment of bacterial skin infections such asimpetigo. In May 2007, retapamulin received approval in theEUfrom theEuropean Medicines Agencyfor the same indication.
Clinical trials have demonstrated its efficacy against certainGram-positivebacteriaincluding MRSA.
Mechanism of action
Retapamulin is an antibacterial agent, specifically aprotein synthesis inhibitor. The medication selectively inhibits bacterial protein synthesis by interacting at a site on the 50S subunit of the bacterial ribosome through an interaction that differs from other antibiotics.
Systemic exposure following topical application through intact skin is low.